RU2650636C2 - Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей - Google Patents

Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей Download PDF

Info

Publication number
RU2650636C2
RU2650636C2 RU2014148544A RU2014148544A RU2650636C2 RU 2650636 C2 RU2650636 C2 RU 2650636C2 RU 2014148544 A RU2014148544 A RU 2014148544A RU 2014148544 A RU2014148544 A RU 2014148544A RU 2650636 C2 RU2650636 C2 RU 2650636C2
Authority
RU
Russia
Prior art keywords
poly
composition
starch
microparticle
microparticles
Prior art date
Application number
RU2014148544A
Other languages
English (en)
Russian (ru)
Other versions
RU2014148544A (ru
Inventor
Брюс Альберт МАЛКОЛМ
Роджер Паулюс Мария ЗУТМУЛЛЕР
Ливен Элвир Колетт Барт
Original Assignee
Янссен Сайенсиз Айрлэнд Юси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48430695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2650636(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Сайенсиз Айрлэнд Юси filed Critical Янссен Сайенсиз Айрлэнд Юси
Publication of RU2014148544A publication Critical patent/RU2014148544A/ru
Application granted granted Critical
Publication of RU2650636C2 publication Critical patent/RU2650636C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014148544A 2012-05-03 2013-05-02 Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей RU2650636C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12166595.4 2012-05-03
EP12166595 2012-05-03
PCT/EP2013/059079 WO2013164380A1 (en) 2012-05-03 2013-05-02 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Publications (2)

Publication Number Publication Date
RU2014148544A RU2014148544A (ru) 2016-06-27
RU2650636C2 true RU2650636C2 (ru) 2018-04-16

Family

ID=48430695

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014148544A RU2650636C2 (ru) 2012-05-03 2013-05-02 Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей

Country Status (17)

Country Link
US (3) US9682096B2 (https=)
EP (1) EP2846767B1 (https=)
JP (1) JP6349304B2 (https=)
KR (1) KR102240042B1 (https=)
CN (1) CN104394846B (https=)
AU (1) AU2013255885C1 (https=)
BR (1) BR112014026957A8 (https=)
CA (1) CA2866230C (https=)
CL (1) CL2014002929A1 (https=)
CO (1) CO7101247A2 (https=)
ES (1) ES2911116T3 (https=)
IN (1) IN2014MN02359A (https=)
MX (1) MX2014013256A (https=)
NZ (1) NZ630040A (https=)
RU (1) RU2650636C2 (https=)
SG (2) SG11201406208QA (https=)
WO (1) WO2013164380A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630040A (en) 2012-05-03 2016-10-28 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
KR20160072140A (ko) * 2013-11-06 2016-06-22 얀센 사이언시즈 아일랜드 유씨 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형
GB201415381D0 (en) * 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
MA44384A (fr) * 2015-05-11 2019-01-23 Janssen Sciences Ireland Unlimited Co Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures
HUE047172T2 (hu) 2015-11-17 2020-04-28 Bioncotech Therapeutics S L Újfajta gyógyszerészeti készítmény, mely egy kétszálú poli-ribonukleotid és egy polialkilén-imin egy komplexét tartalmazó részecskéket tartalmaz
MX2018006575A (es) * 2015-11-30 2018-12-06 Novus Therapeutics Inc Composiciones y metodos para profilaxis otologica y tratamiento.
CN110177545A (zh) 2016-11-16 2019-08-27 爱尔兰詹森科学公司 用于预防上呼吸道感染的聚肌苷酸和聚胞苷酸的制剂
ES2924138T3 (es) 2017-05-17 2022-10-04 Highlight Therapeutics S L Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
WO2020001587A1 (zh) 2018-06-29 2020-01-02 信福(北京)医药科技有限公司 用于增强免疫响应的复合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244505A1 (en) * 2003-12-11 2005-11-03 Higbee Russell G Immunotherapy compositions, method of making and method of use thereof
WO2009116960A1 (ru) * 2008-03-19 2009-09-24 Noga David Anatol Evich Фармацевтическая композиция и способ её получения
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
ATE154241T1 (de) 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
JP2004510724A (ja) * 2000-10-06 2004-04-08 ヤゴテック　アーゲー 分子量の低下した澱粉からなる微粒子中に埋め込まれた免疫学的活性物質を含むワクチン組成物
WO2004041183A2 (en) * 2002-11-01 2004-05-21 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
RU2390351C2 (ru) 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
CN101229378A (zh) 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
AU2005332599B2 (en) 2005-06-08 2012-02-16 Yisheng Biopharma (Singapore) Pte. Ltd. Polyinosinic acid-polycytidylic acid-based adjuvant
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AR067997A1 (es) * 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
CN102281870B (zh) * 2008-12-10 2015-03-04 安徽中人科技有限责任公司 新型控释组合物
CN101491503A (zh) 2008-12-17 2009-07-29 天津瑞普生物技术股份有限公司 一种用于宠物的聚肌胞滴丸及其制备方法
WO2010073247A2 (en) 2008-12-22 2010-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Egfr-homing double-stranded rna vector for systemic cancer treatment
ES2588183T3 (es) 2009-03-31 2016-10-31 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
EP2598145A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
NZ630040A (en) 2012-05-03 2016-10-28 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
KR20160072140A (ko) 2013-11-06 2016-06-22 얀센 사이언시즈 아일랜드 유씨 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244505A1 (en) * 2003-12-11 2005-11-03 Higbee Russell G Immunotherapy compositions, method of making and method of use thereof
WO2009116960A1 (ru) * 2008-03-19 2009-09-24 Noga David Anatol Evich Фармацевтическая композиция и способ её получения
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Малая медицинская энциклопедия. Том 2 / гл. редактор В.И. Покровский // Издательство "Советская энциклопедия", 1991 г. С.319-336. *

Also Published As

Publication number Publication date
US20160296551A1 (en) 2016-10-13
IN2014MN02359A (https=) 2015-08-14
EP2846767B1 (en) 2022-01-26
RU2014148544A (ru) 2016-06-27
US9987300B2 (en) 2018-06-05
AU2013255885C1 (en) 2018-04-26
US20180325939A1 (en) 2018-11-15
NZ630040A (en) 2016-10-28
US9682096B2 (en) 2017-06-20
KR102240042B1 (ko) 2021-04-14
CN104394846A (zh) 2015-03-04
AU2013255885B2 (en) 2017-10-05
ES2911116T3 (es) 2022-05-17
CA2866230A1 (en) 2013-11-07
CN104394846B (zh) 2018-10-19
US20150140042A1 (en) 2015-05-21
BR112014026957A2 (pt) 2017-06-27
CL2014002929A1 (es) 2015-01-16
SG11201406208QA (en) 2014-11-27
HK1203390A1 (en) 2015-10-30
EP2846767A1 (en) 2015-03-18
AU2013255885A1 (en) 2014-09-25
CA2866230C (en) 2020-08-18
SG10201607288VA (en) 2016-10-28
KR20150008855A (ko) 2015-01-23
WO2013164380A1 (en) 2013-11-07
BR112014026957A8 (pt) 2018-01-16
US10485816B2 (en) 2019-11-26
JP2015515968A (ja) 2015-06-04
CO7101247A2 (es) 2014-10-31
MX2014013256A (es) 2015-01-16
JP6349304B2 (ja) 2018-06-27

Similar Documents

Publication Publication Date Title
RU2650636C2 (ru) Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
JP6629216B2 (ja) 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤
US9241898B2 (en) Compositions and methods for controlled delivery of inhibitory ribonucleic acids
CN107820423A (zh) 用于预防和/或治疗上呼吸道感染的聚肌苷酸‑聚胞苷酸(聚(i:c))豌豆淀粉制剂
WO2018091965A1 (en) Formulation of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections
US20160152987A1 (en) Compositions and methods for controlled delivery of inhibitory ribonucleic acids
HK1203390B (zh) 用於治疗上呼吸道感染的聚肌苷酸-聚胞苷酸(聚(i:c))配制品
WO2021236626A1 (en) Mucoretentive antiviral technologies
HK1228749A1 (en) Polyinosinic-polycytidylic acid (poly (i:c) formulations for the treatment of upper respiratory tract infections